On October 28, 2026, the US Department of Health and Human Services (HHS) announced a draft enforcement discretion policy covering six peptides. The notice was scheduled for Federal Register publication on October 30, under docket HHS-OASH-2026-0496. It concerns compounding by state-licensed 503A pharmacies and licensed physicians in the United States.
Several of the six are compounds that research buyers will recognise from the literature. Here is what the notice says, what it does not say, and why it matters for anyone following the evidence.
The six peptides named
- BPC-157 (acetate)
- TB-500 (acetate)
- Epitalon (acetate)
- MOTS-c (acetate)
- KPV (acetate)
- Semax (free base)
Each is listed in Appendix A of the notice with a specific salt form and a limited set of permitted product forms.
What "enforcement discretion" means here
The policy is not an approval. None of the six peptides has gone through the FDA new drug approval process, and the notice does not change that. Instead, HHS states that pharmacies and physicians compounding these substances are not expected to face HHS enforcement action, provided they meet ten listed conditions.
According to summaries from AJMC and the law firm BakerHostetler, those conditions include:
- Bulk material from an FDA-registered manufacturer that follows current good manufacturing practice.
- A certificate of analysis covering identity, purity, potency and contaminants such as endotoxins and heavy metals.
- One active ingredient per product, drawn from the six listed peptides.
- A valid patient-specific prescription.
- Reporting of serious adverse events and product quality problems to FDA's MedWatch program and to state authorities.
- Labeling that states the product is compounded and not for resale.
The policy does not extend to 503B outsourcing facilities. It also does not apply to products sold as research chemicals or dietary supplements.
How long it lasts
HHS describes the policy as interim. It stays in place for each peptide until FDA addresses that substance through rulemaking on the 503A bulk substances list. HHS also says it may revise or withdraw the policy if a safety signal or product quality issue arises. Written comments were invited for two weeks after Federal Register publication, which points to a deadline around November 13, 2026.
The evidence question has not changed
This is the part worth reading slowly. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted in favour of adding several of these peptides to the 503A bulk list. At the same time, FDA's Center for Drug Evaluation and Research (CDER) recommended against listing each of the six. Appendix B of the HHS notice acknowledges those CDER recommendations.
HHS's reasoning in Appendix B leans largely on characterization data, such as lot-specific certificates from registered manufacturers. For several peptides, it describes CDER's safety concerns as theoretical or as reflecting an absence of data rather than an observed harm. For KPV, the document itself uses the phrase "an absence of information rather than an observed signal."
That framing is about manufacturing quality and regulatory risk. It is not new efficacy data. AJMC notes that FDA briefing materials found the available BPC-157 studies to be short, small and insufficient to establish safety or effectiveness. NPR's coverage similarly describes the evidence base for all six as sparse.
Our earlier guides to BPC-157 and TB-500 reach the same conclusion from the published papers. Most of the work is in cell cultures and animal models. For a refresher on why that distinction matters, see Cell studies, animal models and human trials.
Reactions
The response has been divided.
- The Alliance for Pharmacy Compounding called the policy a "more accountable alternative" for people seeking gray-market peptides.
- Public Citizen argued that HHS acted outside the usual rulemaking process and that peptides should go through standard FDA approval.
- The Partnership for Safe Medicines had filed a citizen petition the previous week urging FDA not to follow the July committee recommendation.
Why this matters for researchers
The conditions HHS chose are a useful checklist in their own right. Identity, purity, potency, endotoxin and heavy metal testing are exactly the measurements that separate a well-documented lot from an undocumented one. Our guides to verifying a COA and to purity versus peptide content cover how to read those numbers.
It is also worth being clear about scope. This is a US federal policy about pharmacy compounding. It does not change the status of these substances in Canada, and it does not turn any of them into an authorized medicine. Our note on research materials and authorized medicines in Canada explains how to check Canadian product information.
Sources
- AJMC: HHS draft policy eases enforcement on 6 compounded peptides
- HHS: Enforcement discretion policy, Appendix B (PDF)
- Federal Register public inspection: document 2026-22192
- BakerHostetler: HHS issues enforcement discretion policy on 503A peptide compounding
- NPR via GPB: Trump administration will allow pharmacies to make popular peptides
For laboratory research use only. Not for human or veterinary use.
